Abstracts tagged "steroids"

Abstract Number: 052 • 2023 Pediatric Rheumatology Symposium
Extreme Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA): A Discrete Group of Patients
Yoel Levinsky¹, Rotem Tal², Liora Harel², Shoval Shoham³, Sabreen Abu Ahmad⁴, Yonatan Butbul Aviel⁵, Gil Amarilyo² and Mor Broide³, ¹Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ²Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁴Ruth Rappaport Children's Hospital, Rambam Health Care, Haifa, Israel, ⁵Rambam Medical center, Haifa, Israel
Background/Purpose: Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is the most common periodic fever syndrome in children; by definition, episodes occur every…
Abstract Number: 2161 • 2019 ACR/ARP Annual Meeting
Perioperative Glucocorticoid Management in Patients with Rheumatologic Diseases Undergoing Elective Joint Surgeries
Rashmi Dhital¹, Priyadarshani Sharma ², Izza Mir ² and Anthony Donato ², ¹Reading Hospital ,PA, Shillington, PA, ²Reading Hospital, PA, Reading
Background/Purpose: Over 7 million Americans are estimated to suffer from inflammatory rheumatologic diseases and the rate of joint arthroplasties are nearly 50 % higher among…
Abstract Number: 1944 • 2016 ACR/ARHP Annual Meeting
Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis
Zachary Wallace¹, Eli Miloslavsky², Sebastian H. Unizony³, Na Lu⁴, Gary S. Hoffman⁵, Cees G.M. Kallenberg⁶, Carol A. Langford⁷, Peter A. Merkel⁸, Paul A. Monach⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene William St.Clair¹², Paul Bruntetta¹³, Matthew Cascino¹⁴, Hyon K. Choi¹⁵ and John H. Stone³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Hospital for Special Surgery, Cornell, New York, NY, ¹²Rheumatology and Immunology, Duke University, Durham, NC, ¹³Genentech, Inc., South San Francisco, CA, ¹⁴University of California-San Francisco, San Francisco, CA, ¹⁵Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) treatment includes high dose glucocorticoids (GCs), which are associated with increased body-mass index (BMI), a complication abhorred by patients and associated…
Abstract Number: 3189 • 2016 ACR/ARHP Annual Meeting
Patient Perceptions of Glucocorticoid Side Effects: A Survey of Users in an Online Health Community
Ruth Costello¹, Rikesh Patel¹, Jennifer Humphreys¹, John McBeth¹ and William G Dixon², ¹Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Glucocorticoids (GC) are widely used to treat inflammatory diseases, but are known to have many side effects. Patients’ perspectives of side effects are known…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].